Cipla announces Q2 FY1314 Unaudited Consolidated Financial Results

Mumbai, India, 13th November 2013: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited Consolidated Financial Results for the quarter ended September 30, 2013 (Q2).

Key Financial & Performance Highlights Q2 FY1314 vis-a-vis Q2 FY1213:
(Current year figures include the relevant results of Cipla Medpro and its subsidiaries from the date Cipla Medpro became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable.)

- Sales revenues grew by 14% to ₹2463 cr, up from ₹2167 cr. The previous year’s results included one-time profit share revenues from Escitalopram through our US partner.
- EBITDA was lower by 19.6% at ₹564 cr, down from ₹701 cr
- Profit after tax were lower by by 26.6% at ₹358 cr, down from ₹488 cr
Profit & Loss Highlights:

- Material cost is at 38.4% of net sales in Q2 FY13/14 as compared to 34.7% in Q2 FY12/13.
- EBIDTA decreased by 19.6% and is at 22.5% of income from operations during Q2 FY13/14.
- Profit after tax decreased by 26.6% to ₹358 cr during Q2 FY13/14 as compared to ₹488 cr during Q2 FY12/13.

Performance Review:

**Domestic business:**

- Domestic revenues grew by 11.6% to ₹1040 cr during Q2 FY13/14, up from ₹932 cr during Q2 FY12/13.
- The growth in domestic revenues was largely on account of growth in anti-asthma, urology and COPD therapy segments.

**International business:**

- Exports of formulations grew by 14.9% to ₹1219 cr during Q2 FY13/14, up from ₹1061 cr during Q2 FY12/13. Previous year’s results include one-time profit share revenues from Escitalopram through our US partner.
- Exports of APIs grew by 17.7% to ₹204 cr during Q2 FY13/14, from ₹174 cr during Q2 FY12/13.
- The growth in export revenues was primarily due to growth in anti-retroviral, anti-malaria and anti-allergic segments.

About Cipla:

Cipla is an Indian pharmaceutical multinational which balances cutting edge technology and innovation with the everyday needs of all patients. For more than 70 years, Cipla has been one of the most respected pharmaceutical names in India as well as across 170 countries in which it operates. Cipla continues to drive stakeholder value via its higher purpose of affordable access and “none shall be denied”. Cipla’s contribution has been recognized globally for developing innovative products and drug delivery systems. It played a pioneering role in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day. Cipla has given India and the world many ‘firsts’. The company’s manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA. It provides the highest standard of quality in all its products across the world.

Media Contacts:

**Investor Relations**
Anant Atal
Contact No.: 022 – 23025379
E-Mail: anant.atal@cipla.com

**Corporate Communications**
Jaisingh Balakrishnan
Contact No.: 022 - 23025813
E Mail: jaisingh.krishnan@cipla.com